Dr. James Till
A message from Dr. Alan Bernstein, OC, FRSC, Chair of the Board of Directors of the Canadian Stem Cell Foundation. He is President and CEO of the Canadian Institute for Advanced Research.…
A message from Dr. Alan Bernstein, OC, FRSC, Chair of the Board of Directors of the Canadian Stem Cell Foundation. He is President and CEO of the Canadian Institute for Advanced Research.
When I returned to Canada from New York after leading the Global HIV Vaccine Enterprise, it was relatively easy to decide to become involved with the Canadian Stem Cell Foundation.
One of the most exciting fields of scientific research and promising areas of clinical and translational medicine, stem cells hold huge promise for treating a diverse variety of human diseases, from cancer to neurological disorders to diabetes and more. And Canada punches well above its weight, starting with the 1960s discovery of stem cells by Dr. James Till, who I trained with in the 1970s, and his partner Dr. Ernest ‘Bun’ McCulloch. Many other Canadian scientists have subsequently contributed – with the discovery of cancer stem cells, neural stem cells, mesenchymal stem cells, to name just a few – to make Canada a world leader in the field.
I also agreed to chair the Canadian Stem Cell Foundation’s Board of Directors because I had enormous respect for the people who were already involved, such as former university presidents Drs. Martha Piper and Peter MacKinnon of the Universities of British Columbia and Saskatchewan, respectively. The board also included the Hon. Anne McLellan, who I had worked closely with when I was head of the Canadian Institutes of Health Research and she was Minister of Health.
The list of highly respected people didn’t end with the board. Largely because of the efforts of President and CEO James Price, the Foundation had enlisted prominent Canadians from across the country to join the Till & McCulloch Leadership Circle and show their support for stem cell science and its application to improving health. That was a significant achievement that not only gave the Foundation the credibility it needed but also signaled to the broader Canadian stem cell community that prominent Canadians were active supporters of their goals.
That’s a big reason why Minister of Science Kirsty Duncan, in her mandate letter to the new Canada Research Coordinating Committee last month, named stem cells and regenerative medicine as one of the four key areas for coordination amongst the four federal agencies involved in funding research in this country. This is no accident: it represents the culmination of the efforts of the Foundation and the people associated with it.
In fact, the Foundation has had an important impact on the Federal Government’s appreciation of Canada’s strength in stem cell science and its increased awareness of the important work underway in labs across the country. The now two-year extension of funding to the Stem Cell Network and funding of the $114-million Medicine by Design project at the University of Toronto, much of which is focused on stem cells and regenerative medicine, are indicators of the recognition by government that this is a central component of Canadian research and innovation.
There has been a significant impact on industry, as well. People closely associated with the Foundation, like board member Dr. Allen Eaves, whose Vancouver-based STEMCELL Technologies does business around the globe, have shown you can build successful enterprises and generate the flow of hundreds of millions of dollars into the Canadian economy through stem cell research and development. Similarly, the investment of hundreds of millions of dollars, largely by offshore investors, into BlueRock Therapeutics, a company dedicated to stem cell therapy for cardiac disease, is further evidence of both the strength of Canadian stem cell science and its promise for the treatment of serious human diseases.
Thanks to the efforts of many organizations and many people, the Canadian stem cell effort is in excellent shape. There is positive energy around the country and there are outstanding young people entering the field, which, at the end of the day, is what really matters. They see a great future in stem cells and regenerative medicine.
Because of all this, the Foundation’s board, after an extensive six months of deliberation, decided that our work is now done. The Foundation has accomplished what it was created to do: raise awareness about the importance of stem cell research and the strengths of stem cell science across the country. We were able to make key individuals aware of the value of stem cell research and development – both in terms of improving the health of Canadians and bolstering the Canadian economy.
While it is always easier to start new organizations than end existing ones, the Board of Directors unanimously made the difficult but wise decision to sunset the Foundation and to declare victory. At the same time, the Board also expressed its sincerest thanks to James and to his Executive Assistant, Eileen Emmonds, and Susan DeLisle, Director of Development, for their utmost commitment to the Foundation and its goals and their outstanding efforts on behalf of the Foundation and stem cell science in Canada.
Dr. Alan Bernstein, OC, FRSC, has served as Chair of the Board of Directors of the Canadian Stem Cell Foundation. He is President and CEO of the Canadian Institute for Advanced Research.
Anne McLellan, PC, OC, is best known for her work as a senior cabinet minister in the Jean Chrétien and Paul Martin Liberal Governments, where she was Minister of Natural Resources, Justice Minister, Minister of Public Safety and Emergency Preparedness, Minister of Health, and was named Deputy Prime Minister. …
Anne McLellan, PC, OC, is best known for her work as a senior cabinet minister in the Jean Chrétien and Paul Martin Liberal Governments, where she was Minister of Natural Resources, Justice Minister, Minister of Public Safety and Emergency Preparedness, Minister of Health, and was named Deputy Prime Minister. A law professor at the University of Alberta before entering politics, she won election four times in traditionally Conservative Edmonton ridings by narrow margins, earning her the nickname of Landslide Annie. Her life after politics has been busy: she serves as a Senior Advisor with Bennett Jones LLP and is a Corporate Director with Cameco Corp. and Agrium Inc., and is Chancellor of Dalhousie University. Ms. McLellan is an original member of the Canadian Stem Cell Foundation’s Board of Directors, helping shape and guide the organization from the beginning. Here she shares her thoughts on the Foundation, as it prepares to sunset, and on what needs to happen to move Canada’s stem cell/regenerative medicine sector forward.
Q: Your background is in academics and law, and, of course, federal politics. What piqued your interest in stem cells?
A: When I was Minister of Health, people were learning more about the potential of stem cells. And, of course, doctors in Alberta were developing the Edmonton Protocol for transplanting pancreatic islets to treat diabetes, so I was aware of that and had an interest in what these stem cells could do. After I left politics, a good friend of mine suggested I talk to James Price about the prospect of establishing a stem cell foundation. There was a lot of excitement about the possibilities and I wanted to become involved.
Q: Much of the Foundation’s efforts went into trying to make the Federal Government aware of stem cells’ potential to offer new life-saving treatments for currently incurable diseases and, in turn, boost the Canadian economy by creating companies and jobs. What impact do you think those efforts had?
A: The Foundation raised the profile of stem cell research not only with the Government of Canada but also with the public. Most Canadians – and I was one when I began this journey – didn’t know that Drs. James Till and Ernest McCulloch were responsible for the discovery of stem cells. The Foundation has helped people understand Canada’s historical strength in stem cell research and development and made the case that it would be a shame to let Canada fall behind in terms of the work being done around the world. It helped successive governments understand that this is an area in which we have had an advantage and that we are in danger of losing that advantage if we don’t support it properly.
Q: Have decision-makers in Ottawa embraced that notion?
A: I think they have, though not to the extent we’d like to see. The current Government has provided resources in different ways, including small amounts of money for the continuation of the Stem Cell Network and a larger amount of money for the Centre for Commercialization of Medicine in Toronto. And there have been incremental increases to research dollars. But it is unfortunate that the Government missed an opportunity to fund and work with researchers, clinicians and the private sector to develop a multi-year, national stem cell strategy, which is what the Foundation put forward. Then again, maybe it will happen, because that conversation has begun.
Q: What will it take to move the field forward in Canada?
A: There are a lot of people doing great work in different areas of the sector, but to maximize the potential of the work that’s being done we probably need a new governance structure that brings all the key actors in the stem cell sector together. That structure would drive fundamental research, clinical research and industrial benefits. We need to make sure that people across the stem cell sector are working together. We can’t live in a world of silos or vested interests because, at the end of the day, stem cell research is fundatmentally about improving the well-being of humanity.
(This post is one of several addressing a single subject today in a blog carnival to mark the 10th anniversary of the discovery of induced pluripotent stem cells.…
(This post is one of several addressing a single subject today in a blog carnival to mark the 10th anniversary of the discovery of induced pluripotent stem cells. Please click here to read what other bloggers have to say.)
As summer holidays wind down, most parents are now too familiar with the following question: Are we there yet?
Any family trip to a campground, cottage or Nana’s house in Northport starts off with excitement for all concerned, what with getting up early, packing the car and hitting the road. For kids, though, it’s magical. Then, after about an hour of travelling, regardless what onboard entertainment you’ve arranged, boredom sets in. Two hours into the trip, they’re sure you’re never going to get them there.
Waiting for stem cell discoveries to turn into actual treatments is a lot like that, except that instead of hours, it’s decades. Instead of frustration, the feeling is desperation.
Consider the remarkable discovery, by Japan’s Dr. Shinya Yamanaka, that adult cells extracted from skin can be reprogrammed to an embryonic stem-cell-like state to reproduce any cell required for transplant or to repair organs and tissue. We first heard about these induced pluripotent stem cells (iPS cells) on August 25, 2006. A decade later, we’re still waiting for the Nobel Prize-winning work to turn into treatments.
People, especially those suffering from life-threatening diseases, want to know why we’re still waiting. Unlike bored children, they have far more riding on the answer to the Are we there yet? question. For them, it’s life and death.
At the Canadian Stem Cell Foundation hardly a day goes by that someone doesn’t contact us seeking a stem cell treatment for themselves or a loved one. Today, it was a 48-year-old Toronto man whose doctor had told him his ALS will kill him. At least we could point him in the direction of Dr. Eva Feldman at the University of Michigan, who is trying to get a Phase 2 clinical trial going on a stem cell treatment for ALS.
In all areas of medical research, the wheel turns slowly. It can take decades of lab work and clinical trials and hundreds of millions of dollars to bring new treatments to patients. Consider cervical cancer, the second most common cancer among women. In 1972, Germany’s Dr. Harald zur Hausen started working on the notion that the disease is caused by a virus. It took about 35 years — most of his career — for HPV vaccines to make it to market.
It’s even more complicated for stem cells, a relative newcomer to the scene. While their existence was proven in Canada by Drs. James Till and Ernest McCulloch in the early 1960s, the focus afterwards was on bone marrow stem cells for treating leukemia. Embryonic stem cells have only been in play since 1998. Realistically, iPS cells are still the new cells on the block.
Cell-based therapies represent a whole new way of thinking about treating diseases, and regenerative medicine is a disruptive technology. Unlike a vaccine or a drug, the actual therapy isn’t an easy thing to grasp for industry, whose commitment is crucial in moving things from the lab bench to the hospital bed.
What’s needed, then, is an innovative approach. We need to think bigger. That’s why our Foundation is championing the Canadian Stem Cell Strategy, a private/public partnership to deliver up to 10 new curative therapies to the clinic within 10 years. Crafted in consultation with 150 scientists, doctors, leaders from health charities, industry experts and philanthropists, it is backed by an in-depth KPMG study and endorsed by an international panel of experts.
The private sector is already at the table, pledging more than $350 million toward R&D — almost one-quarter of the $1.5-billion Strategy. Other industry partners, health charities and leading Canadian philanthropists are prepared to make major contributions upon demonstration of a federal commitment to the plan. We’re asking the Government of Canada, as part of its Innovation Agenda, to provide one-third, about $50 million annually over 10 years.
Are we there yet? Clearly not. But a coordinated national road map can get us there.
We are at a crucial moment in time for stem cell research and development in Canada.
For almost two decades the field of stem cells and regenerative medicine “has been long on promise, short on product,” according to a feature article in the current issue Biotechnology Focus magazine.…
We are at a crucial moment in time for stem cell research and development in Canada.
For almost two decades the field of stem cells and regenerative medicine “has been long on promise, short on product,” according to a feature article in the current issue Biotechnology Focus magazine.
But that is changing quickly, the article points out. In clinical trials underway across Canada, researchers are using stem cells to treat diabetes, heart attacks, osteoarthritis and spinal cord injury to name just a few. There is a growing feeling that the field is on the verge of delivering new treatments that will change the lives of patients suffering from chronic, debilitating diseases.
That sentiment was also on display at last week’s Till & McCulloch Meetings in Toronto. The Canadian Stem Cell Foundation is a partner with the retiring Stem Cell Network, the Canadian Centre for Regenerative Medicine and the Ontario Institute for Regenerative Medicine, who co-host the premier stem cell event in Canada. It brings together some 400 scientists, clinicians and industry leaders to share insights into how to move the field forward.
Chosen as the 2015 Till & McCulloch Award Winner, Dr. Timothy Kieffer of the University of British Columbia gave the keynote lecture at the closing session and shared his optimism at the progress his lab and others are making towards defeating diabetes.
Drawing from a paper published in Nature Biotechnology last year, he described how his team reversed diabetes in mice using insulin-producing cells derived from human stem cells. Looking forward to moving his work into clinical trials, Dr. Kieffer says it’s just a matter of time before stem cells provide the needed source of cells to replace insulin injections, sparing millions of diabetics of the need for needles and rigorously monitoring their blood sugar levels several times a day. He predicts this will happen within 10 years.
In short, good things are happening. Obstacles are being overcome. Cures are on their way. The horizon is getting closer and we can see the possibilities more clearly now.
Our Foundation is proud to be a major sponsor of the Till & McCulloch Meetings, Canada’s premier stem cell research event.…
Our Foundation is proud to be a major sponsor of the Till & McCulloch Meetings, Canada’s premier stem cell research event.
Named after Drs. James Till and Ernest McCulloch, the conference brings together Canada’s leading stem cell scientists, clinicians, bioengineers and ethicists, as well as representatives from industry, government, health and NGO sectors from around the world. The 2015 Till & McCulloch Meetings will take place in Toronto from October 26-28, 2015 at the Sheraton Centre Hotel.
For more information about the conference or to register click here.
This year’s session will feature several scientists whose innovative research has been highlighted in this space, including Drs. Jeff Biernaskie, Connie Eaves, Tim Kieffer and Ivar Mendez. As well, Foundation President & CEO James Price and Board Chair Dr. Alan Bernstein will update delegates on the progress being made to secure support for implementing the Canadian Stem Cell Strategy & Action Plan. To show your support for the Strategy, click here.
Dr. Andy Becker, one of the true pioneers of stem cell science, has died in Toronto at age 80.
Dr. Andy Becker, one of the true pioneers of stem cell science, has died in Toronto at age 80.
Dr. Becker was the lead author of the 1963 paper, published in Nature, that definitively demonstrated the existence of stem cells. Using chromosomal markers, he retraced their steps after they had generated the three types of precursor cells needed to make blood.
“It was a key contribution to our early experimental investigations of stem cells,”Dr. Jim Till, who was Dr. Becker’s PhD advisor at the time, wrote via email. “His combination of talent and persistence was what was needed to complete this challenging and innovative research. I’m still amazed at what he accomplished. I doubt if anyone else, at that time, could have succeeded in the way that Andy did.”
Dr. Becker worked closely with Drs. Ernest McCulloch and Till who, in 1961, had successfully shown that single cells drawn from bone marrow could produce colony-forming units containing the precursor cells required to make white blood cells, red blood cells and platelets. That paper laid the foundation for stem cell science.
A third Till & McCulloch paper — also published in 1963 but with Dr. Lou Siminovitch as lead author –proved that stem cells not only differentiate into new cells but also have the capacity to self-renew in order to keep the process going throughout our lifetimes. Combined, the three papers essentially defined stem cells and set the stage for regenerative medicine.
Dr. Becker’s paper proved just how tenacious a researcher he could be. The chromosomal marker method was nothing if not painstakingly frustrating, given the rudimentary technology available at the time. In the University of Toronto Press book Dreams & Due Diligence, Dr. Becker’s wife, Prof. Clelia Ganoza, explains that he had a “killer instinct” for research, which meant that “the goal is the important issue and the obstacles to overcome are just needed lessons towards this end.”
As the Toronto Star obituary explains, Dr. Becker, who was also a medical doctor, not only did seminal work with stem cells but contributed greatly to the development of recombinant DNA technology.
Here at the Canadian Stem Cell Foundation, our hearts go out to Dr. Becker’s family, especially Prof. Ganoza, his wife of 47 years.
The news last week that Dr. Janet Rossant had won the 2015 Gairdner Wightman Award should have come as no big surprise.…
The news last week that Dr. Janet Rossant had won the 2015 Gairdner Wightman Award should have come as no big surprise. The head of research at SickKids Hospital in Toronto, Dr. Rossant perfectly fits the profile of the Wightman winner: a scientist who has demonstrated outstanding national leadership in medicine and medical science.
However, the announcement did give us another reason to celebrate: it brought the Canadian Stem Cell Foundation’s Gairdner Award connections to four — so far.
Dr. Rossant (1) who chairs our Foundation’s Science Leadership Council, has led the way in crafting Canada’s public policy regarding stem cell research and is the immediate Past President of the International Society for Stem Cell Research. She also is an articulate advocate for the Canadian Stem Cell Strategy & Action that sets out how Canada can lead the way to deliver five to 10 new stem cell therapies to the clinic within 10 years. (See the Globe & Mail piece she co-authored here).
With the announcement, Dr. Rossant joins Dr. Alan Bernstein (2), Chair of our Board of Directors, as a fellow Gairdner Wightman winner. Dr. Bernstein, now President & CEO of the Canadian Institute for Advanced Research, won the Wightman in 2008 for his “outstanding contribution to Canadian health research as a scientist, research institute director and as the inaugural President of the Canadian Institutes of Health Research.”
Dr. Bernstein’s stem cell connection goes all the way back to his PhD studies with Dr. Jim Till, co-discoverer of stem cells (with Dr. Ernest McCulloch) in the late 1960s/early 1970s at the Ontario Cancer Institute (OCI). Dr. Till mentored Dr. Bernstein in much the same way that Dr. Bernstein encouraged Dr. Rossant when she came to work at the Samuel Lunenfeld Research Institute (now the Lunenfeld-Tanenbaum Research Institute) at Toronto’s Mount Sinai Hospital in 1985.
Dr. Till (3) is a Gairdner International Award winner, having picked up the prize with Dr. McCulloch back in 1969. His connection to the Foundation? He was original member of the Board of Directors when the Foundation began life in 2006 and has been a trusted advisor ever since. In fact, his “Spleen Team” jersey, from when he led the OCI squad that unveiled the mysteries of hematopoietic stem cells, hangs in a place of honour in the Foundation’s office in Ottawa.
Then there is Dr. Samuel Weiss (4), who won his Canada Gairdner International Award in 2008 in large part for his 1992 discovery of neural stem cells in the brains of adult mammals, which sparked new approaches for brain cell replacement and repair. Dr. Weiss, who leads the Hotchkiss Brain Institute at the University of Calgary, preceded Dr. Rossant as Chair of our Science Leadership Council and was also a member of the Foundation’s Board.
Quite honestly, we’re proud to be associated with these outstanding scientists. That they have chosen to help us as we advocate for the advancement of stem cell research and development to deliver safe, new and effective treatments for an array of diseases is truly inspiring. And we look forward to finding out who will be (5).
Dr. Harry Atkins’ success in treating a rare disease that can turn active, healthy people into living statues is getting the national attention it deserves this week, thanks to the Journal of the American Medical Association’s publication of his paper, Autologous Stem Cell Transplantation for Stiff Person Syndrome.…
Dr. Harry Atkins’ success in treating a rare disease that can turn active, healthy people into living statues is getting the national attention it deserves this week, thanks to the Journal of the American Medical Association’s publication of his paper, Autologous Stem Cell Transplantation for Stiff Person Syndrome.
The JAMA Neurology paper describes two Canadian women who have had all symptoms of their Stiff Person Syndrome (SPF) disappear thanks to a stem cell treatment that Dr. Atkins and his team at the Ottawa Hospital have developed. Readers of this blog will be familiar with one of the women’s stories — we told you all about Tina Ceroni back in December After our post, Canada AM featured Tina and Dr. Atkins.
This week’s reports, including Elizabeth Payne’s excellent news feature (the “living statue” description is hers) that appeared in the Ottawa Citizen and the National Post, explain how SPS, which strikes about one in a million people, triggers episodes in which muscles seize up uncontrollably, leaving a person rigid. Sheryl Ubelacker of the Canadian Press describes it this way in the Toronto Star:
“SPS is characterized by episodes of stiffness in the muscles and painful muscle spasms, which can be brought on by stress, loud noises or emotional distress. Some people with the disorder are so disabled they are unable to walk or move and may isolate themselves at home to avoid triggering an attack.”
Ms Payne’s story also tells of a third woman, a 53-year-old mother of six named Ingrid Steppan who was told she would likely die from her SPS. A recent transplant patient, she has now “put her wheelchair and walker away.”
Success with MS, Crohn’s and other autoimmune conditions
Dr. Atkins has used this technique with other autoimmune diseases, including Multiple Sclerosis (where he led a multi-year clinical trial involving about 30 patients) Crohn’s disease and neuromyelitis optica. The process involves extracting a patient’s bone marrow stem cells, then purifying and fortifying them. After the patient undergoes extreme chemotherapy, in which their immune system is effectively destroyed, the purified and fortified stem cells are put back to build a new disease-free immune system.
A modest and soft-spoken man, Dr. Atkins does not used the word “cured” when he talks about the patients who have had success with this treatment. He refers to his patients as “in remission.” For Jennifer Molson, an MS patient, that remission has lasted more than a decade. And in the case of Jelissa Morgan, the treatment has allowed her to overcome her crippling neuromyelitis optica and will be resuming her nursing career in September.
The success that Dr. Atkins is having is encouraging and offers great hope for the future. But it also harkens back to the past: the procedure he is refining can be traced back to the groundbreaking work the Canadians Jim Till and Ernest McCulloch did in proving the existence of stem cells in the early 1960s. It’s an area of medical science where Canada researchers excel. And people like Tina Ceroni, Jennfer Molson, Jelissa Morgan … and now Ingrid Steppan are living proof.
Since the first award was handed out in 1901, the Nobel Prize has become globally regarded as the most prestigious recognition of intellectual achievement.…
Since the first award was handed out in 1901, the Nobel Prize has become globally regarded as the most prestigious recognition of intellectual achievement. What’s amazing, however, is how often the Nobel committee has glaringly overlooked researchers behind outstanding discoveries that changed the practice of medicine.
Pioneers of Medicine Without a Nobel Prize, just published by the United Kingdom’s Imperial College Press, tells the stories of giants in medical science who somehow never won the Nobel Prize for Physiology or Medicine.
Among the 15 featured scientists are:
• heart transplant pioneers Drs. Christiaan Barnard and Norman Shumway;
• Dr. Richard Doll, who made the link between smoking and lung cancer;
• Drs. Inge Edler and Carl Helmuth Hertz, who developed ultrasound technology; and
• Dr. Akira Endo, the discoverer of statins.
One chapter of the book, written by the Foundation’s Joe Sornberger, is dedicated to Drs. James Till and Ernest McCulloch, the “fathers of stem cell research.” The two Canadians proved the existence of stem cells in the early 1960s at the Ontario Cancer Institute, while working on the sensitivity of bone marrow cells to radiation in mice.
Dr. Till still remembers the “Eureka” moment, when his partner Dr. McCulloch showed him a piece of graph paper on which he had illustrated that the more marrow cells were transplanted, the more bumps on the spleens appeared. After two years of work, Till and McCulloch showed that the bumps were formed by individual transplanted cells, which had proliferated and given rise to blood-forming cells.
That Dr. Till & McCulloch were somehow overlooked for the Nobel Prize in Physiology or Medicine is inexplicable to many. As a previous post explained, there was some thought that Dr. Till would be handed his long overdue Nobel Laureate’s wreath two years ago alongside Japan’s Dr. Shinya Yamanaka, who discovered induced pluripotent stem cells. (Dr. McCulloch died in 2011, making him ineligible). Canada has not brought home a Nobel in this category in over 90 years — not since Dr. Frederick Banting, discoverer of insulin, won in 1923.
Then again, when amazing giants such as Drs. Willem Kolff and Belding Scribner, who developed the Renal Haemodialysis, are left off the Nobel list, Drs. Till & McCulloch are in brilliant company.
For those who would like the full story of this amazing Canadian success story, you can purchase a copy of Mr. Sornberger’s book, Dreams & Due Diligence, published by University of Toronto Press, here.
To mark the Toronto’s 180th birthday this week, the Toronto Star has offered its readers 180 portraits of “the people who helped shape the city” from its Muddy York beginnings to its current status as one the world’s great centres.…
To mark the Toronto’s 180th birthday this week, the Toronto Star has offered its readers 180 portraits of “the people who helped shape the city” from its Muddy York beginnings to its current status as one the world’s great centres.
The list contains most of those you would expect — Father of Confederation George Brown, jazz great Oscar Peterson and business tycoon Kenneth Thomson — and a few you wouldn’t, including “Call In The Army” Mayor Mel Lastman, bank robber Edwin Alonzo Boyd and the Maple Leafs former owner and convicted fraudster Harold Ballard.
But also included are Drs. James Till and Ernest McCulloch, lauded as “the fathers of stem cell research” and as mentors to “generations of scientists in stem cell research, a field that promises to transform medical treatment and health care.”
Despite the enormity of their achievements, Till & McCulloch are virtually unknown across Canada. When CBC ran its Greatest Canadian competition 10 years ago, the two men who discovered stem cells did not even crack the top 100. (No. 1 was Tommy Douglas, while hockey commentator Don Cherry placed seventh.) And there is nothing — no public building, no elementary school, no street, not so much as a plaque — honouring Till & McCulloch in the city where they did their remarkable research.
Also on the Star list under the category of Trailblazers and Innovators is Dr. Tak Mak, the medical scientist who discovered the T-Cell receptor. Dr. Mak is one of those who was mentored by Till and McCulloch and has gone on record as saying McCulloch “was behind me when the rest of the world thought I was crazy.” One of the world’s leading cancer researchers, Dr. Mak has been featured in this space for his recent foray into developing a “sharpshooter” drug to attack tumours.
The Star recognition is a great first step, an indication that the public is finally beginning to appreciate these two medical research giants. Now, if the powers that be could be convinced to rechristen Sherbourne Street, where their original the Ontario Cancer Institute and Princess Margaret Hospital lab was located, as Till & McCulloch Way, that would really be something.